Trajenta Duo 2.5 mg/850 mg Tablet

Trajenta Duo 2.5 mg/850 mg Tablet is an anti-diabetic medicine. It is a combination of Metformin (850mg) and Linagliptin (2.5mg). It is prescribed to treat type 2 diabetes mellitus in adults.

It works by controlling blood sugar levels in people with diabetes. This medicine functions by enhancing the action of insulin and lowering the quantity of sugar that the liver produces. It should be taken with food at the same time each day to get effective results. Don't take more than the recommended dose.​

• Type 2 diabetes mellitus

Trajenta Duo 2.5 mg/850 mg Tablet may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.

Common side effects include:

• Nausea
• Headache
• Dizziness
• Vomiting
• Fatigue
• Skin rash
• Abnormal liver function

Seek medical attention in case of any unusual or severe side effects immediately.

• Take Trajenta Duo 2.5 mg/850 mg Table t in dosage as prescribed by the doctor. Dosage and the duration determined as per the patients health condition.
• This tablet should be swallowed as a whole with water. Don't crush, chew, or break the tablet. It should be taken with food. Never skip a dose or double dose.​
  

• Trajenta Duo 2.5 mg/850 mg Tablet is an anti-diabetic medicine. It is a combination of Metformin (850mg) and Linagliptin (2.5mg). This tablet increases the body's tolerance to insulin, reduces the liver's synthesis of glucose, and slows down the intestines' absorption of glucose.
• Linagliptin is known as a DPP-4 inhibitor that minimizes blood sugar by stimulating the pancreas to secrete more insulin. It lowers fasting as well as post-meal sugar levels also together they can provide better control of blood sugar.
  
  

• Chandrasekaran, S., Kalaivani, K., & Thamizhanban, D. Bioequivalence Assessment of the Fixed Dose Combination of Linagliptin/Metformin (2.5 mg/850mg) Film Coated Tablets in Healthy Human Subjects: A Randomized, Open-Label, Two-Period Crossover Study. https://www.texilajournal.com/medicine/article/3380-bioequivalence-assessment-of
• Chatterjee, S., & Jat, R. K. (2021). Formulation and evaluation of immediate release tablet dosage form of linagliptin and metformin hydrochloride. Journal of Drug Delivery & Therapeutics, 11. https://jddtonline.info/index.php/jddt/article/view/4831
• Bhargava, A. (2015). Linagliptin/metformin HCl (fixed combination therapy) for the treatment of Type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism, 10(4), 353-363. https://pubmed.ncbi.nlm.nih.gov/30293498/
• Ross, S. A., Rafeiro, E., Meinicke, T., Toorawa, R., Weber-Born, S., & Woerle, H. J. (2012). Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Current medical research and opinion, 28(9), 1465-1474. - https://pubmed.ncbi.nlm.nih.gov/22816729/
• Haak, T. (2015). Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes. Clinical Medicine Insights: Endocrinology and Diabetes, 8, CMED-S10360.Chandrasekaran, S., Kalaivani, K., & Thamizhanban, D. Bioequivalence Assessment of the Fixed Dose Combination of Linagliptin/Metformin (2.5 mg/850mg) Film Coated Tablets in Healthy Human Subjects: A Randomized, Open-Label, Two-Period Crossover Study.
• Ji, L., Zinman, B., Patel, S., Ji, J., Bailes, Z., Thiemann, S., & Seck, T. (2015). Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with type 2 diabetes: a double-blind randomized trial. Advances in therapy, 32(3), 201-215.